Dendreon to restructure operations, close N.J. plant, cut 600 positions

Wednesday, August 1, 2012

Biotechnology company Dendreon has announced a strategic restructuring plan designed to accelerate the company’s profitability and future growth, which includes re-configuring Dendreon’s manufacturing model with the closure of its Morris Plains, N.J. manufacturing facility, restructuring administrative functions and strengthening the company’s commercial functions.

[Read More]

Mymetics ropes in Dendreon vets

Wednesday, April 11, 2012

Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.

[Read More]

Dendreon to cut 500 jobs

Friday, September 9, 2011

Dendreon has reported it will cut 500 jobs as it seeks to trim expenses in light of diminished sales expectations for its high-priced Provenge prostate cancer vaccine, according to Reuters.

[Read More]